Integra Lifesciences (IART) AI Stock Analysis

• Market Cap: $812.89M
• Dividend Yield: N/A
• Average Volume (3M): 682.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: 4.99%
• EPS Growth: -7151.40%
• Country: US
• Employees: 4,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.83
• Shares Outstanding: 77,937,210
• 10 Day Avg. Volume: 691,147
• 30 Day Avg. Volume: 682,692
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.58
• P/FCF Ratio: -30.70
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 0.95
• Enterprise Value/Ebitda: 3.66
• 1Y Price Target: $12.00
• Price Target Upside: 15.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 2.35
• Revenue Forecast (FY): $1.68B

• Rating: 47 Neutral
• Price Target: $11.00 ▲(5.47% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held down primarily by the sharp 2025 profitability/revenue deterioration and weakened cash generation, with technicals also leaning weak (below key long-term moving averages). The earnings call provides partial offset via guidance for improved cash flow, modest growth, and deleveraging, but tariff/remediation and organic growth pressure keep risk elevated.

Positive Factors

Diversified Product Portfolio

Integra’s breadth across neurosurgery, orthopedics and wound care and its recurring consumable/implantable revenue create durable, cross‑segment demand. This diversification reduces dependence on any single franchise, supports steady aftermarket sales and enables cross‑sell and distribution leverage over multiple quarters.

Material Balance‑Sheet Repair

A sharp decline in debt and much lower debt/equity materially increases financial flexibility. This stronger capital structure supports funding remediation, Braintree capex and R&D without immediate refinancing stress, enabling management to execute multi‑quarter deleveraging and operational recovery plans.

R&D and Product Commercialization Push

Management has prioritized innovation and commercial activity with relaunches, new launches and clinical programs. Combined with an expanded leadership/R&D focus and manufacturing upgrades, this strengthens the long‑term product pipeline and supports sustainable revenue recovery as supply and regulatory issues normalize.

Negative Factors

Severe 2025 Profitability Shock

The large 2025 revenue and profitability reset is structurally significant: a near‑term collapse in volume and deep negative margins erode pricing power, customer relationships and returns on invested capital. Recovering prior profitability and restoring earnings quality will likely take multiple quarters and sustained execution.

Weakened Cash Generation

Material deterioration in cash conversion and negative free cash flow constrain self‑funding for remediation, capex and R&D. With limited internal cash generation, the company faces higher execution risk, greater reliance on balance‑sheet actions and slower ability to invest in growth initiatives over the medium term.

Tariff & Remediation Uncertainty

Nonrecoverable tariffs and ongoing product remediation (e.g., MediHoney) have persistent margin and revenue impacts. Regulatory and tariff outcomes are unresolved, potentially permanently raising costs or delaying product returns to market, which undermines margin sustainability and prolongs organic growth headwinds.

Integra Lifesciences Business Overview & Revenue Model

Company Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Integra LifeSciences generates revenue through the sale of its medical devices and products across several key segments, including neurosurgery, orthopedics, and advanced wound care. The company’s revenue model is primarily based on direct sales to hospitals and healthcare providers, as well as through distribution agreements and partnerships with other medical companies. Key revenue streams include sales of surgical instruments, biologic products, and tissue regeneration solutions. Additionally, Integra benefits from recurring revenue through its implantable devices and consumable products, which are frequently used in surgical procedures. Strategic partnerships and collaborations with healthcare organizations and research institutions also contribute to its earnings by expanding product offerings and market reach.

Integra Lifesciences Financial Statement Overview

Summary

Recent fundamentals are weak: the income statement reflects a sharp 2025 deterioration (large net loss and major revenue decline), and cash flow weakened with low operating cash flow and negative free cash flow. The balance sheet is a relative positive with materially reduced debt, but returns and overall profitability pressure remain significant.

Income Statement

Revenue was broadly stable through 2021–2024 but collapsed in 2025 (annual revenue down ~47%). Profitability deteriorated sharply: the company moved from modest profitability in 2022–2023 to near-breakeven losses in 2024, then to a very large net loss in 2025 (net margin roughly -32%). Earlier periods showed solid gross margin and healthy operating profitability (2021–2022), but the 2025 reset overwhelms the multi-year track record and raises concerns about earnings quality and business disruption.

Balance Sheet

Leverage improved materially in 2025, with debt dropping sharply and debt-to-equity falling to ~0.21 versus ~0.90–1.28 in 2020–2024, which is a clear balance-sheet positive. However, profitability pressure shows up in returns on equity, swinging from ~10% in 2021–2022 to slightly negative in 2024 and deeply negative in 2025, indicating equity is currently not earning an adequate return. Total assets and equity remain sizable, but the recent earnings collapse is a key risk to balance-sheet strength over time.

Cash Flow

Operating cash flow remained positive across the period, including 2025, which provides some downside support. That said, cash generation weakened meaningfully versus prior years (well below 2021–2022 levels), and free cash flow fell sharply in 2024 and again in 2025, with extremely negative growth reported in 2025. The company’s cash flow no longer comfortably supports profitability and investment needs the way it did in 2021–2022, signaling reduced cash conversion and higher execution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.64B	1.61B	1.54B	1.56B	1.54B
Gross Profit	845.23M	882.06M	884.74M	970.31M	944.64M
EBITDA	-326.20M	193.29M	255.96M	384.60M	366.33M
Net Income	-516.47M	-6.94M	67.74M	180.55M	169.07M
Balance Sheet
Total Assets	3.60B	4.04B	3.78B	3.89B	3.78B
Cash, Cash Equivalents and Short-Term Investments	263.74M	273.57M	309.10M	456.66M	513.45M
Total Debt	215.83M	1.98B	1.68B	1.63B	1.67B
Total Liabilities	2.56B	2.49B	2.19B	2.09B	2.10B
Stockholders Equity	1.04B	1.55B	1.59B	1.80B	1.68B
Cash Flow
Free Cash Flow	-31.05M	24.96M	73.09M	217.38M	264.35M
Operating Cash Flow	50.38M	129.38M	139.96M	264.47M	312.43M
Investing Cash Flow	-108.06M	-390.81M	-94.18M	-58.58M	-161.44M
Financing Cash Flow	28.34M	237.86M	-229.93M	-251.95M	-98.23M

Integra Lifesciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Negative. The current price of 10.43 is below the 20-day moving average (MA) of 11.30, below the 50-day MA of 11.97, and below the 200-day MA of 13.03, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 35.46 is Neutral, neither overbought nor oversold. The STOCH value of 29.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IART.

Integra Lifesciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	69 Neutral	$1.58B	23.28	17.82%	―	29.47%	23.24%
BVS	64 Neutral	$725.83M	78.09	4.97%	―	1.58%	―
CNMD	61 Neutral	$1.41B	30.45	6.60%	2.02%	4.69%	-51.57%
AXGN	56 Neutral	$1.59B	-90.49	-1.90%	―	18.72%	85.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50 Neutral	$536.73M	-5.71	-24.60%	―	4.31%	3.26%
IART	47 Neutral	$812.89M	-1.55	-39.90%	―	4.99%	-7151.40%

Integra Lifesciences Corporate Events

Integra Lifesciences Adopts New Severance Program

On December 11, 2025, Integra LifeSciences announced the adoption of a change in control severance program effective January 1, 2026, for certain executives, including key figures like Lea Knight and Robert T. Davis, Jr. This program, which renews the expiring one, offers severance packages and benefits in the event of employment termination following a company control change by December 31, 2026. The program includes lump sum payments, COBRA premium subsidies, and outplacement services, with provisions to avoid excise tax penalties. The term of the program extends automatically upon a change in control or qualifying termination, impacting the company’s executive retention strategy and stakeholder interests.

The most recent analyst rating on (IART) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.